Abstract: The compound N-[N'acetyl(glycinyl)]-5-methoxytryptamine, of formula (I) ##STR1## exhibited markedly prolonged immunostimulating activity. The method of preparation and the method of use are described.

Abstract: 2-benzoylamino-3,5-dibromo-N-(4-hydroxycyclohexyl)benzylamine of formula (I), and pharmaceutically acceptable acid addition salts have antitussive and mucus regulating activities.

Abstract: A pharmaceutical composition (orally or parenterally administered) containing glycyl-p-amino-pyridine monoacetate alone or together suitable carriers, which shows surprising anti-amnesic and anti-Alzheimer properties, is described.

Abstract: 3-Methyl-3-(4-acetylaminophenoxy)-2,4-dioxabenzocyclohexanone-1, having formula I ##STR1## exhibits an high analgesic, antiinflammatory and antipiretic activity along with a prolonged action and an excellent gastric and systemic tolerability.

Abstract: Compound of general formula I ##STR1## and its addition salts with a pharmaceutically acceptable acid is described. The compound is prepared by reacting bis-(2-(3,4-dimethoxy-phenyl)ethyl)amine with formaldehyde in a reducing medium. The compound is effective in the treatment of cardiovascular diseases and disturbances in cerebral circulation.

Abstract: N-carbethoxy-4-thiazolidine-carboxylic acid of formula I ##STR1## and the alkali, alkali-earth of basic amino acid salts thereof have therapeutic activities in the affections of respiratory system.

Abstract: The compound of formula (I): ##STR1## N-cyclohexyl-N"-4-(2-methylthioquinolyl)-N'-2-thiazolyl-guanidine and pharmaceutically acceptable salts thereof is a valuable antiinflammatory, analgesic and antipyretic agent.The compound of the invention may be formulated with conventional pharmaceutically acceptable carriers or diluents to provide a pharmaceutical composition.

Abstract: The compound I ##STR1## prepared by reacting m-nitrobenzaldehyde, ethyl .beta.-aminocrotonate and 2-piperidinoethanol acetoacetate, is endowed with valuable pharmacological properties namely calcium antagonistic activity in vitro and in vivo.

Abstract: The present invention relates to the 3-[N-(2-mercapto-propionyl-amino-acetyl)]-tetrahydro-thiazolyl-4-carboxyli c acid and pharmaceutical compositions containing it, endowed with a marked inhibitory activity of the angiotensin converting enzyme (ACE).

Abstract: The present invention concerns tetraethylene glycol monoesters with 2-arylpropionic acids (known as anti-inflammatory agents). Said esters, while being endowed with the characteristics of low toxicity and gastric injuring effects shown by the related acids, differ advantageously from the latter because their anti-inflammatory activity is much more prolonged, and their bioavailability markedly better.

Abstract: The present invention concerns diesters of polyethylene glycols (with n ranging between 4 approximately and 100 approximately) with 2-arylpropionic acids (known as anti-inflammatory agents). These esters, while possessing all the characteristics of low toxicity and gastric injuring effects shown by the related acids, differ advantageously from the latter because their anti-inflammatory activity is much more prolonged, and their bio-availability markedly better.

Abstract: 3-(2-Methoxy-phenoxy)-3-methyl-benzo-2,4-dioxacyclohexanone of formula ##STR1## a process for its preparation through reaction among the chloride of acetylsalicylic acid, guaiacole and pyridine; pharmaceutical compositions containing it.

Abstract: Benzamides of formula I ##STR1## are described, in which R=CH.sub.3, Cl or COOCH.sub.3 ; R' is a member selected from the group of dialkylamine, pyrrolidine, piperidine, and morpholine radicals. CH.sub.2 R' is in position ortho, meta, or para with respect to the carbonyl group; and their salts thereof with pharmaceutically acceptable acids are described. The novel compounds exhibit local anaesthetic and antiarrhythmic activity.

Abstract: Compositions useful for platelet antiaggregation activity are described, which contain as the active ingredient N-(2-chlorobenzyl)-pyrrolidine or a pharmacologically compatible salt thereof with an organic or an inorganic acid, and at least one pharmaceutically acceptable carrier or excipient. The compositions in the form of an aqueous solution are administered orally in the dose of 2-8 mgs/kg, preferably 3 mgs/kg body weight twice a day. The compositions may also be administered intravenously or endoperitoneally. The compositions may be administered in the form of capsules, ampoules or in the form of oily suspensions, solutions or emulsions.